Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

le Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales, S., de la Haba-Rodríguez, J.
Foilsithe 2013

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

le Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A
Foilsithe 2014